BR112023002458A2 - Métodos de tratamento da gota - Google Patents
Métodos de tratamento da gotaInfo
- Publication number
- BR112023002458A2 BR112023002458A2 BR112023002458A BR112023002458A BR112023002458A2 BR 112023002458 A2 BR112023002458 A2 BR 112023002458A2 BR 112023002458 A BR112023002458 A BR 112023002458A BR 112023002458 A BR112023002458 A BR 112023002458A BR 112023002458 A2 BR112023002458 A2 BR 112023002458A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- treatment methods
- pegylated uricase
- gout
- gout treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Liquid Crystal Substances (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Glass Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063063826P | 2020-08-10 | 2020-08-10 | |
| US202163148982P | 2021-02-12 | 2021-02-12 | |
| PCT/US2021/045350 WO2022035828A1 (en) | 2020-08-10 | 2021-08-10 | Methods of treating gout |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002458A2 true BR112023002458A2 (pt) | 2023-05-02 |
Family
ID=80247297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002458A BR112023002458A2 (pt) | 2020-08-10 | 2021-08-10 | Métodos de tratamento da gota |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230301999A1 (https=) |
| EP (2) | EP4588513A3 (https=) |
| JP (1) | JP2023537403A (https=) |
| KR (1) | KR20230086660A (https=) |
| CN (1) | CN116261463A (https=) |
| AU (1) | AU2021324665A1 (https=) |
| BR (1) | BR112023002458A2 (https=) |
| CA (1) | CA3189100A1 (https=) |
| IL (1) | IL300536A (https=) |
| MX (1) | MX2023001740A (https=) |
| WO (1) | WO2022035828A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG161247A1 (en) | 2005-04-11 | 2010-05-27 | Savient Pharmaceuticals Inc | Variant forms of urate oxidase and use thereof |
| US9377454B2 (en) | 2009-06-25 | 2016-06-28 | Crealta Pharmaceuticals Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| CN116637177A (zh) | 2016-11-11 | 2023-08-25 | 好利恩治疗美国公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| WO2020160322A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple) |
| WO2020160325A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| EP4588513A3 (en) * | 2020-08-10 | 2025-10-22 | Horizon Therapeutics USA, Inc. | Methods of treating gout |
| WO2024088213A1 (en) * | 2022-10-24 | 2024-05-02 | Westlake Therapeutics (Shanghai) Co., Limited | Combination to induce specific immune tolerance |
| US12201413B2 (en) | 2023-03-01 | 2025-01-21 | Washington University | Free breathing dynamic contrast enhanced (DCE) liver MR imaging |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE498409T1 (de) | 1998-08-06 | 2011-03-15 | Mountain View Pharmaceuticals | Peg-uricase konjugate und verwendung davon |
| US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| WO2000008196A2 (en) * | 1998-08-06 | 2000-02-17 | Duke University | Urate oxidase |
| MX2007012548A (es) | 2005-04-11 | 2008-03-11 | Savient Pharmaceuticals Inc | Formas variantes de urato oxidasa y uso de las mismas. |
| SG161247A1 (en) | 2005-04-11 | 2010-05-27 | Savient Pharmaceuticals Inc | Variant forms of urate oxidase and use thereof |
| JP5033177B2 (ja) | 2006-04-12 | 2012-09-26 | サビエント ファーマセウティカルズ インク． | 陽イオン界面活性剤によるタンパク質の精製 |
| US9377454B2 (en) | 2009-06-25 | 2016-06-28 | Crealta Pharmaceuticals Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| KR20180120753A (ko) * | 2016-03-11 | 2018-11-06 | 셀렉타 바이오사이언시즈, 인크. | Peg화 우리카제의 제제 및 용량 |
| CN116637177A (zh) | 2016-11-11 | 2023-08-25 | 好利恩治疗美国公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| ES3036482T3 (en) * | 2017-03-11 | 2025-09-19 | Cartesian Therapeutics Inc | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| WO2020160325A1 (en) * | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| WO2020160324A1 (en) * | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| EP4588513A3 (en) * | 2020-08-10 | 2025-10-22 | Horizon Therapeutics USA, Inc. | Methods of treating gout |
-
2021
- 2021-08-10 EP EP25163173.5A patent/EP4588513A3/en active Pending
- 2021-08-10 CA CA3189100A patent/CA3189100A1/en active Pending
- 2021-08-10 WO PCT/US2021/045350 patent/WO2022035828A1/en not_active Ceased
- 2021-08-10 KR KR1020237008344A patent/KR20230086660A/ko active Pending
- 2021-08-10 JP JP2023509723A patent/JP2023537403A/ja active Pending
- 2021-08-10 MX MX2023001740A patent/MX2023001740A/es unknown
- 2021-08-10 US US18/020,761 patent/US20230301999A1/en active Pending
- 2021-08-10 IL IL300536A patent/IL300536A/en unknown
- 2021-08-10 EP EP21856554.7A patent/EP4192581A4/en not_active Withdrawn
- 2021-08-10 BR BR112023002458A patent/BR112023002458A2/pt unknown
- 2021-08-10 AU AU2021324665A patent/AU2021324665A1/en active Pending
- 2021-08-10 CN CN202180053221.3A patent/CN116261463A/zh active Pending
-
2022
- 2022-02-09 US US17/668,015 patent/US20220323445A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023001740A (es) | 2023-04-05 |
| CA3189100A1 (en) | 2022-02-17 |
| EP4588513A2 (en) | 2025-07-23 |
| AU2021324665A1 (en) | 2023-04-13 |
| CN116261463A (zh) | 2023-06-13 |
| WO2022035828A1 (en) | 2022-02-17 |
| IL300536A (en) | 2023-04-01 |
| KR20230086660A (ko) | 2023-06-15 |
| JP2023537403A (ja) | 2023-08-31 |
| US20220323445A1 (en) | 2022-10-13 |
| EP4588513A3 (en) | 2025-10-22 |
| EP4192581A1 (en) | 2023-06-14 |
| US20230301999A1 (en) | 2023-09-28 |
| EP4192581A4 (en) | 2024-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023002458A2 (pt) | Métodos de tratamento da gota | |
| CY1116463T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| NO20052348L (no) | Behandling av hemoragisk sjokk | |
| UA104634C2 (xx) | Пегильована l-аспарагіназа $пегилированная l-аспарагиназа | |
| DK1169059T3 (da) | Docetaxel i kombination med rhuMAb HER2 til behandling af cancere | |
| NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
| BR0209147A (pt) | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais | |
| BR0313282A (pt) | Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| BR112014029954A2 (pt) | tratamento de tumores sólidos usando coenzima q10 | |
| BR112023021131A2 (pt) | Tratamento de tremor essencial | |
| NO20064287L (no) | Dalbavancin-materialer for behandling av bakterielle infeksjoner | |
| MX2023003993A (es) | Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina. | |
| DE60222383D1 (de) | Medikament zur verabreichung von amifostin und verwandten wirkstoffen | |
| MX2008001520A (es) | Composiciones de tizanidina y metodos de tratamiento usando las composiciones. | |
| NO20076657L (no) | Kombinasjonsterapi av cancer med AZD2171 og gemcitabin | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| TW200511999A (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone | |
| BRPI0410761A (pt) | uso de leucina, e, composição para administração entérica a pacientes | |
| MX2025000682A (es) | Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma | |
| TW200719903A (en) | Compositions for the treatment of neoplasms | |
| BR112012011316A2 (pt) | tivozanib e temsirolimus em combinação | |
| PH12023551170A1 (en) | Il-7 binding proteins and their use in medical therapy | |
| MX2022011000A (es) | Metodos y composiciones para identificar y tratar canceres sensibles a los inhibidores de glutaminasa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |